HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation...
- Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected in Q4 2023...
Topline Results Expected Third Quarter 2023 Long COVID Afflicts Approximately 19% of Patients Following COVID-191, and is Expected to be...
KNOXVILLE, TN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on...
Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena’s...
– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-deleted tumors...
Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023...
Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer Frank Weber, MD, current Chief Medical...
SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology...
SEATTLE, WA / ACCESSWIRE / August 4, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage...
DUBLIN--(BUSINESS WIRE)--The "United States Women Health Laboratory Testing Market by Hereditary Cancer, Reproductive Health and Infectious Diseases, Prenatal Screening and...
TURKU, Finland and BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical...
Pivotal Study of NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient PopulationLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO),...
SAN FRANCISCO, CA / ACCESSWIRE / August 3, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the...
Live moderated webcast fireside chat on August 3rd at 11:35 AM ETHOUSTON, TX / ACCESSWIRE / August 3, 2023 /...
Company continued to see rapid progression and acceleration of enrollment with 180 patients enrolled to date across 46 clinical trial...
Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62Company expecting 2023...
FORT LEE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and...
These efficiencies plus revenue growth expected to continue the positive momentumNEW HAVEN, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Specialty...
- First of its kind, non-surgical, permanent birth control option begins enrollment in landmark trial -ATLANTA, Aug. 03, 2023 (GLOBE...